Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benralizumab - Kyowa Hakko Kirin/MedImmune

Drug Profile

Benralizumab - Kyowa Hakko Kirin/MedImmune

Alternative Names: Benra; BIW-8405; BIW-8405-IL-5R; Fasenra; KHK 4563; MEDI-563

Latest Information Update: 21 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioWa
  • Developer AstraZeneca; Cincinnati Children's Hospital Medical Center; Kyowa Hakko; Kyowa Hakko Kirin; MedImmune; National Jewish Medical and Research Center
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Churg-Strauss syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Chronic obstructive pulmonary disease; Nasal polyps
  • Phase II Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis
  • Phase I/II Eosinophilic gastroenteritis

Most Recent Events

  • 04 Jan 2019 AstraZeneca intends to launch benralizumab in UK in May 2019
  • 04 Jan 2019 Benralizumab receives approval for Asthma from NICE in UK
  • 26 Nov 2018 Benralizumab receives Orphan Drug status for Churg-Strauss syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top